Zevra Therapeutics (ZVRA) Prepaid Assets (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Prepaid Assets came in at $4.9 million in Q1 2026, up 31.28% YoY from $3.8 million in Q1 2025, and down 29.35% on a QoQ basis from $7.0 million in Q4 2025.
Zevra Therapeutics (ZVRA) Prepaid Assets (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Prepaid Assets data on file, last reported at $4.9 million in Q1 2026.
- Quarterly Prepaid Assets rose 31.28% year-over-year to $4.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 31.28% YoY) and the FY2025 annual result came in at $7.0 million, up 72.7% from the prior year.
- Prepaid Assets slipped to $4.9 million in Q1 2026, from $7.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $7.4 million in Q3 2025 to a low of -$426000.0 in Q2 2022.
- A 5-year average of $2.8 million and a median of $2.3 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets plunged 128.25% — and 2023, when it surged 489.91%.
- Tracing ZVRA's Prepaid Assets over 5 years: stood at $1.7 million in 2022, then tumbled by 30.57% to $1.2 million in 2023, then jumped by 245.73% to $4.1 million in 2024, then soared by 72.7% to $7.0 million in 2025, then decreased by 29.35% to $4.9 million in 2026.
- The last three Prepaid Assets figures came in at $4.9 million (Q1 2026), $7.0 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.79 Mn |
| Mar 31, 2026 | 4.94 Mn |
| Dec 31, 2025 | 7.00 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Sep 30, 2024 | 2.28 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Sep 30, 2023 | 1.66 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | -426,000.00 |
| Jun 30, 2022 | -426,000.00 |
| Mar 31, 2022 | 454,000.00 |
| Dec 31, 2021 | 637,000.00 |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 395,000.00 |